Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00885495 · ClinicalTrials.gov registry record · Phase 1
Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study
A Phase 1 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00885495 is a Phase 1 study that has completed, run by University of Cincinnati. The registered enrollment target is 17 participants.
The verdict
NCT00885495, a Phase 1 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This is a phase I, open-label, controlled drug interaction study to determine the effects of darunavir plus ritonavir on the pharmacokinetics of the hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, rosuvastatin, in HIV-1-seronegative subjects.
Interventions
- DRUG darunavir, ritonavir, rosuvastatin
- DRUG rosuvastatin, darunavir, ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2009-01 |
| Est. Completion | 2010-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00885495
The ClinicalTrials.gov registry entry for NCT00885495 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which darunavir, ritonavir, rosuvastatin is the first listed.
NCT00885495 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00885495 about?
NCT00885495 is a clinical study titled "Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study". This is a phase I, open-label, controlled drug interaction study to determine the effects of darunavir plus ritonavir on the pharmacokinetics of the hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, rosuvastatin, in HIV-1-seronegative subjects.
What is the current status of trial NCT00885495?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2009-01. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00885495?
The interventions under investigation include: darunavir, ritonavir, rosuvastatin (DRUG), rosuvastatin, darunavir, ritonavir (DRUG).
Who is sponsoring clinical trial NCT00885495?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.